SYNTHESIS, MOLECULAR DOCKING AND CYTOTOXIC STUDY OF 7-METHOXY-2-(3-METHOXYLPHENYL)-1-BENZOFURAN-5-CARBALDEHYDE

Bapu R. Thorat^a, Ravindra Jagtap^b, Vaishali B. Thorat^c, Annasaheb Khemanar^d and Ramesh S. Yamgar^e

a. P. G. and Research centre, Ismail Yusuf Arts, Science and Commerce College, Jogeshwari (E), Mumbai 400060.
b. JJT University, Rajasthan.
c. IES, Junior College, Bandra (E), Mumbai.
d. Institute of Science, Fort, Mumbai
e. Patkar Varde College, Goregaon (W), Mumbai

Abstract: The 7-methoxy-2-(3-methoxylphenyl)-1-benzofuran-5-carbaldehyde was synthesized by known literature method (Wittig reaction approach) from vanillin. To deduce the anticancer and antibacterial activity of the 7-methoxy-2-(3-methoxylphenyl)-1-benzofuran-5-carbaldehyde, it is docked with different biomarkers of cancer cell and bacteria. Grid was generated for each oncoproteins by specifying the active site amino acids. The binding model of best scoring analogue with each protein was assessed from their G-scores and disclosed by docking analysis using the XP visualizer tool. An analysis of the receptor-ligand interaction studies revealed that 7-methoxy-2-(3-methoxylphenyl)-1-benzofuran-5-carbaldehyde is most active against 4FNY and 1VOM biomarkers and have the features to prove themselves as anticancer drugs. It shows strong cytotoxicity against human lung (A-459) and breast (MCF-07) cell lines.

Keywords: Benzofurans, Molecular docking, Anticancer, 1VOM, 4FNY, Wittig reaction.

1. Introduction:

Molecular modelling can accelerate and guide to the chemist or scientist for drug design and contribute to the understanding of the biochemical functions of gene products. These molecular modelling techniques used for the study of organic/inorganic/bio molecules use theoretical and computationally based methods to model or mimic the behavior of molecule/s and have been widely applied for understanding and predicting the behavior of molecular systems [1]. Molecular modelling has become an essential part of contemporary drug discovery processes of new molecules. A traditional approach for drug discovery of molecules relies on step-wise synthesis and screening of large numbers of compounds to optimize activity profiles of molecule which is to act as drug; this is extremely time consuming and costly method takes decades of years. The cost of these processes has increased significantly in recent years [2], and it takes over a decade for a very small fraction of compounds to pass the drug discovery pipeline from initial screening hits or leads, chemical optimization, and clinical trials before launching into the market as drug. The approaches and methodologies used in drug design have changed over time, exploiting and

driving new technological advances to solve the varied bottlenecks found along the way. There are several programs used for docking, including DOCK-6, FlexX, GLIDE, GOLD, FRED, and SURFLEX has been assessed and these programs proved to generate reliable poses in numerous docking studies.

Until 1990, the major issues were lead discovery and chemical synthesis of drug-like molecules; the emergence of combinatorial chemistry,[4] gene technology, and high-throughput tests [5,6] has shifted the focus, and poor absorption, distribution, metabolism, and excretion (ADME) properties of new drugs captured more attention [7].

Protein docking is a computational problem to predict the binding of a protein with potential interacting partners. The docking problem can be defined as: Given the atomic coordinates of two molecules, predict their correct bound association [3], which is the relative orientation and position after interaction. There are three key components in protein docking: (1) representation of the molecules, (2) searching and (3) scoring of the potential solutions.

2. Materials and Methods:

Docking software used: Maestro 9.9 (Schrodinger). Protein Crystal Structures (PDB ID: 1RJB, 3FDN, 3LAU, 4BBG, 3V3M, 1BAG, 3F8S, 2b4J, 1Z92, 1YC, 4FNY, 2BOU, 1UFQ, 1VOM, 2AZ1, 1KDR, 3MK2, 1TE6, 1P62). These proteins are characterized by Ramachandran plot.

| IYCRMDM2 bound to the trans-activation domain of p53Homo sapiensIZ92Interleukin-2 with its alpha receptorHomo sapiens2b4JRecognition between hiv-1 integrase and ledgf/p75Homo sapiens3F8SDipeptidyl peptidase IV (DPP-4) in complex with inhibitorHomo sapiens1BAGAlpha-amylase from bacillus subtilis complexed with maltopentaoseBacillus subtilis1RJB (FLT3)FI cytokine receptorHomo sapiens3FDNSerine/threonine-protein kinase 6Homo sapiens3LAUArora 2 kinaseHomo sapiens4BBGHuman kinesin eg5 -like protein kif11Homo sapiens3V3M3C-like proteinase [severe acute respiratory syndrome coronavirus (sars-cov) 3cl protease]Dictyostelium discoideum1VOMDictyostelium myosinDictyostelium discoideumDictyostelium discoideum2BOUEGF domains 1,2,5 of human emr2, a 7-tm immune system moleculeHomo sapiens3MK2Placental alkaline phosphataseHomo sapiens1KDR (Chain A)Cytidine monophosphate kinaseEscherichia coli1UFQUridine-cytidine kinase 2Homo sapiens | PDB of protein | Worked as | Source |
|---|----------------|---|-------------------|
| 1Z92Interleukin-2 with its alpha receptorHomo sapiens2b4JRecognition between hiv-1 integrase and ledgf/p75Homo sapiens3F8SDipeptidyl peptidase IV (DPP-4) in complex with inhibitorHomo sapiens1BAGAlpha-amylase from bacillus subtilis complexed with maltopentaoseBacillus subtilis1BAGAlpha-amylase from bacillus subtilis complexed with maltopentaoseBacillus subtilis3F8NSerine/threonine-protein kinase 6Homo sapiens3LAUArora 2 kinaseHomo sapiens3V3M3C-like proteinase [severe acute respiratory syndrome coronavirus (sars-cov) 3cl protease]Homo sapiens1VOMDictyostelium myosinDictyostelium discoideum2BOUEGF domains 1,2,5 of human emr2, a 7-tm immune system moleculeHomo sapiens3MK2Placental alkaline phosphataseHomo sapiens1KDR (Chain A)Cytidine monophosphate kinaseEscherichia coli1UFQUridine-cytidine kinase 2Homo sapiens | 4ASE | Vascular endothelial growth factor receptor 2 | Homo sapiens |
| 2b4JRecognition between hiv-1 integrase and ledgf/p75Homo sapiens3F8SDipeptidyl peptidase IV (DPP-4) in complex with inhibitorHomo sapiens1BAGAlpha-amylase from bacillus subtilis complexed with maltopentaoseBacillus subtilis1RJB (FLT3)FI cytokine receptorHomo sapiens3FDNSerine/threonine-protein kinase 6Homo sapiens3LAUArora 2 kinaseHomo sapiens4BBGHuman kinesin eg5 -like protein kif11Homo sapiens3V3M3C-like proteinase [severe acute respiratory syndrome coronavirus (sars-cov) 3cl protease]Homo sapiens1TE6Gamma enolase [human neuron specific enolase]Homo sapiens1WOMDictyostelium myosinDictyostelium discoideum2BOUEGF domains 1,2,5 of human emr2, a 7-tm immune system moleculeHomo sapiens3MK2Placental alkaline phosphataseHomo sapiens1KDR (Chain A)Cytidine monophosphate kinaseEscherichia coli1P62Deoxycytidine kinase 2Homo sapiens | 1YCR | MDM2 bound to the trans-activation domain of p53 | Homo sapiens |
| 3F8SDipeptidyl peptidase IV (DPP-4) in complex with inhibitorHomo sapiens1BAGAlpha-amylase from bacillus subtilis complexed with maltopentaoseBacillus subtilis1RJB (FLT3)FI cytokine receptorHomo sapiens3FDNSerine/threonine-protein kinase 6Homo sapiens3LAUArora 2 kinaseHomo sapiens4BBGHuman kinesin eg5 -like protein kif11Homo sapiens3V3M3C-like proteinase [severe acute respiratory syndrome coronavirus (sars-cov) 3cl protease]Homo sapiens1TE6Gamma enolase [human neuron specific enolase]Homo sapiens1VOMDictyostelium myosinDictyostelium discoideum2BOUEGF domains 1,2,5 of human emr2, a 7-tm immune system moleculeHomo sapiens3MK2Placental alkaline phosphataseHomo sapiens1KDR (Chain A)Cytidine monophosphate kinaseEscherichia coli1UFQUridine-cytidine kinase 2Homo sapiens | 1Z92 | Interleukin-2 with its alpha receptor | Homo sapiens |
| inhibitorinhibitor1BAGAlpha-amylase from bacillus subtilis complexed with maltopentaoseBacillus subtilis1RJB (FLT3)FI cytokine receptorHomo sapiens3FDNSerine/threonine-protein kinase 6Homo sapiens3LAUArora 2 kinaseHomo sapiens4BBGHuman kinesin eg5 -like protein kif11Homo sapiens3V3M3C-like proteinase [severe acute respiratory syndrome coronavirus (sars-cov) 3cl protease]Homo sapiens1TE6Gamma enolase [human neuron specific enolase]Homo sapiens1VOMDictyostelium myosinDictyostelium discoideum2BOUEGF domains 1,2,5 of human emr2, a 7-tm immune system moleculeHomo sapiens3MK2Placental alkaline phosphataseHomo sapiens1KDR (Chain A)Cytidine monophosphate kinaseEscherichia coli1P62Deoxycytidine kinase 2Homo sapiens | 2b4J | Recognition between hiv-1 integrase and ledgf/p75 | Homo sapiens |
| maltopentaoseHomo sapiens1RJB (FLT3)FI cytokine receptorHomo sapiens3FDNSerine/threonine-protein kinase 6Homo sapiens3LAUArora 2 kinaseHomo sapiens4BBGHuman kinesin eg5 -like protein kif11Homo sapiens3V3M3C-like proteinase [severe acute respiratory syndrome coronavirus (sars-cov) 3cl protease]Homo sapiens1TE6Gamma enolase [human neuron specific enolase]Homo sapiens1VOMDictyostelium myosinDictyostelium discoideum2BOUEGF domains 1,2,5 of human emr2, a 7-tm immune system moleculeHomo sapiens3MK2Placental alkaline phosphataseHomo sapiens1KDR (Chain A)Cytidine monophosphate kinaseEscherichia coli1UFQUridine-cytidine kinase 2Homo sapiens | 3F8S | | Homo sapiens |
| 3FDN Serine/threonine-protein kinase 6Homo sapiens 3LAU Arora 2 kinaseHomo sapiens 4BBG Human kinesin eg5 -like protein kif11Homo sapiens 3V3M 3C-like proteinase [severe acute respiratory syndrome coronavirus (sars-cov) 3cl protease]Homo sapiens 1TE6 Gamma enolase [human neuron specific enolase]Homo sapiens 1VOM Dictyostelium myosinDictyostelium discoideum 2BOU EGF domains 1,2,5 of human emr2, a 7-tm immune system moleculeHomo sapiens 3MK2 Placental alkaline phosphataseHomo sapiens 1KDR (Chain A) Cytidine monophosphate kinaseEscherichia coli 1P62 Deoxycytidine kinase 2Homo sapiens | 1BAG | | Bacillus subtilis |
| 3LAU Arora 2 kinaseHomo sapiens 4BBG Human kinesin eg5 -like protein kif11Homo sapiens 3V3M 3C-like proteinase [severe acute respiratory syndrome coronavirus (sars-cov) 3cl protease]Homo sapiens 1TE6 Gamma enolase [human neuron specific enolase]Homo sapiens 1VOM Dictyostelium myosinDictyostelium discoideum 2BOU EGF domains 1,2,5 of human emr2, a 7-tm immune system moleculeHomo sapiens 3MK2 Placental alkaline phosphataseHomo sapiens 1KDR (Chain A) Cytidine monophosphate kinaseEscherichia coli 1UFQ Uridine-cytidine kinase 2Homo sapiens | 1RJB (FLT3) | FI cytokine receptor | Homo sapiens |
| 4BBGHuman kinesin eg5 -like protein kif11Homo sapiens3V3M3C-like proteinase [severe acute respiratory syndrome coronavirus (sars-cov) 3cl protease]Homo sapiens1TE6Gamma enolase [human neuron specific enolase]Homo sapiens1VOMDictyostelium myosinDictyostelium discoideum2BOUEGF domains 1,2,5 of human emr2, a 7-tm immune system moleculeHomo sapiens3MK2Placental alkaline phosphataseHomo sapiens1KDR (Chain A)Cytidine monophosphate kinaseEscherichia coli1UFQUridine-cytidine kinase 2Homo sapiens | 3FDN | | Homo sapiens |
| 3V3M 3C-like proteinase [severe acute respiratory syndrome coronavirus (sars-cov) 3cl protease]Homo sapiens 1TE6 Gamma enolase [human neuron specific enolase]Homo sapiens 1VOM Dictyostelium myosinDictyostelium discoideum 2BOU EGF domains 1,2,5 of human emr2, a 7-tm immune system moleculeHomo sapiens 3MK2 Placental alkaline phosphataseHomo sapiens 1KDR (Chain A) Cytidine monophosphate kinaseEscherichia coli 1P62 Deoxycytidine kinase 2Homo sapiens | 3LAU | Arora 2 kinase | Homo sapiens |
| coronavirus (sars-cov) 3cl protease]Image: Text of the second secon | 4BBG | Human kinesin eg5 -like protein kif11 | Homo sapiens |
| 1TE6Gamma enolase [human neuron specific enolase]Homo sapiens1VOMDictyostelium myosinDictyostelium discoideum2BOUEGF domains 1,2,5 of human emr2, a 7-tm immune system moleculeHomo sapiens3MK2Placental alkaline phosphataseHomo sapiens1KDR (Chain A)Cytidine monophosphate kinaseEscherichia coli1P62Deoxycytidine kinaseEscherichia coli1UFQUridine-cytidine kinase 2Homo sapiens | 3V3M | | Homo sapiens |
| 2BOUEGF domains 1,2,5 of human emr2, a 7-tm immune system moleculediscoideum3MK2Placental alkaline phosphataseHomo sapiens1KDR (Chain A)Cytidine monophosphate kinaseEscherichia coli1P62Deoxycytidine kinaseEscherichia coli1UFQUridine-cytidine kinase 2Homo sapiens | 1TE6 | Gamma enolase [human neuron specific enolase] | Homo sapiens |
| system molecule3MK2Placental alkaline phosphataseHomo sapiens1KDR (Chain A)Cytidine monophosphate kinaseEscherichia coli1P62Deoxycytidine kinaseEscherichia coli1UFQUridine-cytidine kinase 2Homo sapiens | 1VOM | Dictyostelium myosin | |
| 1KDR (Chain A)Cytidine monophosphate kinaseEscherichia coli1P62Deoxycytidine kinaseEscherichia coli1UFQUridine-cytidine kinase 2Homo sapiens | 2BOU | | |
| 1KDR (Chain A)Cytidine monophosphate kinaseEscherichia coli1P62Deoxycytidine kinaseEscherichia coli1UFQUridine-cytidine kinase 2Homo sapiens | 3MK2 | Placental alkaline phosphatase | Homo sapiens |
| 1UFQUridine-cytidine kinase 2Homo sapiens | 1KDR (Chain A) | Cytidine monophosphate kinase | |
| | 1P62 | Deoxycytidine kinase | Escherichia coli |
| | 1UFQ | Uridine-cytidine kinase 2 | |
| | 2AZ1 | Nucleoside diphosphate kinase | Escherichia coli |
| 4FNY ALK tyrosine kinase receptor Homo sapiens | 4FNY | ALK tyrosine kinase receptor | Homo sapiens |

2.1. Protocol for ligand-receptor docking:

The three dimensional structures of all proteins were taken from the PDB database. The native autoinducer and all water molecules were removed from basic protein structures.

Hydrogen were added using the templates for the protein residues. The three-dimensional structure of the ligand [7-methoxy-2-(3-methoxylphenyl)-1-benzofuran-5-carbaldehyde] was constructed. The ligand was then energy-minimized in the in-built ChemSketch module of the software.

2.2. Docking:


The active site of each protein were first identified and defined using an eraser size of 5.0 Å. The ligand was docked into the active site separately using the 'Flexible Fit' option. The ligand-receptor site complex was subjected to '*in situ*' ligand minimization which was performed using the in-built CHARMm forcefield calculation. The nonbond cutoff and the distance dependence was set to 11 Å and ($\varepsilon = 1R$) respectively. The determination of the ligand binding affinity was calculated using the shape-based interaction energies of the ligand with the protein. Consensus scoring with the top tier of s=10% using docking score used to estimate the ligand-binding energies.

3. Study of molecular structure and properties:

Molecular structure has been studied by different molecular programs such as Avogadro, Glide, etc. The molecular parameters such as non-bonded atom bond lengths, bond angles, Drug likeness property has been studied by VEGA ZZ 3.0.3 program.

Fig 1: Van der Waal surface, bond length and bond angles of 7-methoxy-2-(3-methoxylphenyl)-1benzofuran-5-carbaldehyde





Distance between the atoms which are not attached directly





Fig 2: Most stable orientations of groups 7-methoxy-2-(3-methoxylphenyl)-1-benzofuran-5-carbaldehyde



| carbaldehyde | |
|---------------------------------|--|
| Molecular formula: | C ₁₇ H ₁₄ O ₄ |
| Total Energy | 17.8445 kcal/mol. |
| Molecular weight | 298.356 g/mol. |
| m/z values | 282.09 (100), 283.09 (18.4), 284.10 (1.6) |
| Elemental analysis (% analysis) | C – 72.33, H – 5.0, O – 22.67. |
| H - donor | 4 |
| H – bond acceptor | 0 |
| Energy of HOMO | -11.474 eV |
| Energy of LUMO | -04.831 eV |
| Formal charge | 0 |
| Gibbs free energy | -28.29 kJ/mol (at 298K & 1atm) |
| Ovality | 1.518348 |
| Partition coefficient | 4.355799 |
| Heat of formation | -309.6 kJ/mol (at 298K & 1atm) |
| Ideal gas thermal capacity | 304.908 J/mol.K |
| Water solubility | 0 mg/lit |
| Stereochemistry | C(8)-C(7): (Z) |
| LogP | 2.872 (n-Octanol/water) |
| Mol Refractivity | 77.0618 cm ³ /mol |
| Lipinski Rule | 282.089;4;0;4;4.356 |
| Henry's Law Constant | 7.842 |
| Connolly Accessible Area | 527.721 A ² |
| Num Rotatable Bonds | 4 bonds |
| Polar Surface Area | 48.67 A^2 |
| Sum of charges | 0.0 |
| Solvation energy | -4.857432 eV |
| Electrostatic Energy | -90.9830 kcal/mol |
| Dipole | 2.7335 Debye |
| Membrane energy | 0.931765 eV |

 Table 2: Some molecular functions / properties of 7-methoxy-2-(3-methoxylphenyl)-1-benzofuran-5carbaldehyde

 Table 2: Application of VEGA ZZ 3.0.3 for study of Druglikeness propety:


| Property | | 7-methoxy-2-(3-methoxylphenyl)-1- benzofuran-5-carbaldehyde |
|-----------------------------|------------|--|
| By using Lipinski rule of f | ive | |
| Molecular weight | Dalton | 282.290 |
| No. of H-bond acceptor | (< 10) | 04 |
| No. of H-bond donor | (< 5) | 00 |
| Virtual Log P | (< 5) | 4.039 |
| Comment | • | Ok |
| By using Ghose's rule of fi | ve | |
| Molecular weight | Dalton | 282.290 |
| Number of atoms | 20 - 70 | 35 |
| Vertual Log P | -0.4 - 5.6 | 4.039 |
| Molar refractivity | 40 - 130 | 80.3925 |
| Comment | | Ok |

4. Experimental Work:

A mixture of phosphonium salt (1.5 g, 3.2 mmol), 3-methoxybenzoyl chloride (3.2 mmol) and triethylamine (0.75 g, 7.4 mmol) in toluene (30 ml) was heated under reflux for 5 hr. The completion of reaction was confirmed by TLC. The reaction mixture was cooled to room temperature and adds 20 ml water to it and shake well. The organic layer was separated, washed with 10 ml water and dried by anhydrous sodium sulphate. Toluene was distilled off under reduced pressure and the (faint yellow) solid obtained was purified by column chromatography (using 35% ethyl acetate in pet ether as mobile phase) to afford the solid 7-methoxy-2-(3-methoxyphenyl)-1-benzofuran-5-carbaldehyde (62 %), yellow solid, m.p. 125-127 0 C.

FT-IR (KBr): 2954, 1685, 1554, 1482, 1344, 1214, 1143, 846, 775, 682 cm⁻¹.

NMR (300 MHz) (CDCl₃; ŏppm): $C_{17}H_{14}O_4$ (Mol. Wt. 282.290 g/mol): 3.84 (s, 3H, -OCH₃-m); 4.03 (s, 3H, OCH₃-p); 6.99 (d, J = 3Hz, 1H, Ar-H); 7.42 (dd, J = 3 & 5Hz, 1H, Ar-H); 7.38 (d, J = 3Hz, 1H, Ar-H); 7.50-7.59 (m, 3H); 7.85 (s, 1H); 10.00 (s, 1H, -CHO). Fig 3: NMR Spectra of 7-methoxy-2-(3-methoxyphenyl)-1-benzofuran-5-carbaldehyde (6j)



4.1. Generation of docking sites:

The binding sites for the docking are generated by using Glide software. The site of the protein having more site score is considered for the docking of ligand. The site which having maximum *site points*, locate on the site in different colours as **hydrophobic** and **hydrophilic** maps. The hydrophilic maps are further divided into **donor**, **acceptor**, and **metal-binding regions**. Other properties characterize the binding site in terms of the **size** of the site, **degrees of enclosure** by the protein and exposure to solvent, **tightness** with which the site points interact with the receptor, **hydrophobic** and **hydrophilic character** of the site and the balance between them, and degree to which a ligand might **donate or accept** hydrogen bonds. These all properties are summarised in following table 3.

The docking site scores, size, volume exposure, enclosure, contact, hydrophobic and hydrophilic nature, donor and acceptor ratio of all proteins are shown in table 3.

| | Site | | 8 | | F | | | | | | don/ |
|---------|-------|------|--------|---------|----------|-----------|---------|--------|--------|---------|-------|
| protein | Score | size | Dscore | volume | exposure | enclosure | contact | phobic | philic | balance | acc |
| 3V3M | 0.913 | 75 | 0.852 | 258.279 | 0.611 | 0.715 | 0.927 | 0.473 | 1.200 | 0.395 | 0.510 |
| 4BBG | 1.040 | 223 | 1.034 | 503.867 | 0.522 | 0.758 | 1.035 | 1.274 | 1.108 | 1.150 | 0.725 |
| 3LAU | 1.046 | 116 | 1.095 | 437.325 | 0.609 | 0.703 | 0.883 | 1.245 | 0.819 | 1.520 | 0.749 |
| 3FDN | 1.047 | 206 | 1.02 | 760.774 | 0.531 | 0.768 | 0.964 | 0.758 | 1.170 | 0.648 | 0.880 |
| 1RJB | 1.073 | 100 | 1.037 | 195.51 | 0.492 | 0.807 | 1.124 | 0.668 | 1.186 | 0.563 | 0.706 |
| 1BAG | 0.989 | 143 | 0.989 | 425.663 | 0.676 | 0.681 | 0.849 | 0.343 | 1.103 | 0.311 | 0.478 |
| 3F8S | 1.009 | 146 | 1.012 | 489.118 | 0.647 | 0.711 | 0.855 | 0.298 | 1.089 | 0.274 | 0.762 |
| 2b4J | 1.074 | 121 | 1.136 | 552.321 | 0.752 | 0.728 | 0.860 | 1.321 | 0.745 | 1.773 | 1.456 |
| 1Z92 | 0.961 | 95 | 1.013 | 316.246 | 0.749 | 0.599 | 0.699 | 0.396 | 0.805 | 0.492 | 1.427 |
| 1YCR | 0.755 | 41 | 0.754 | 90.552 | 0.653 | 0.620 | 0.849 | 1.171 | 0.675 | 1.735 | 2.006 |
| 1TE6 | 1.05 | 193 | 0.849 | 507.64 | 0.515 | 0.773 | 0.993 | 0.008 | 1.703 | 0.004 | 0.595 |
| 1VOM | 1.074 | 222 | 1.114 | 618.772 | 0.605 | 0.754 | 0.934 | 1.022 | 0.853 | 1.198 | 0.708 |
| 2BOU | 0.464 | 16 | 0.375 | 45.962 | 0.807 | 0.542 | 0.727 | 0.134 | 1.000 | 0.134 | 1.433 |
| 3MK2 | 0.872 | 73 | 0.914 | 179.389 | 0.731 | 0.574 | 0.712 | 0.632 | 0.717 | 0.882 | 0.623 |
| 1KDR | 1.047 | 276 | 0.963 | 749.112 | 0.472 | 0.768 | 1.009 | 0.463 | 1.343 | 0.345 | 0.661 |
| 1P62 | 1.048 | 200 | 0.948 | 372.841 | 0.438 | 0.770 | 1.007 | 0.49 | 1.393 | 0.352 | 0.520 |
| 1UFQ | 1.009 | 176 | 1.042 | 756.315 | 0.656 | 0.684 | 0.862 | 0.51 | 0.947 | 0.538 | 0.931 |
| 2AZ1 | 1.121 | 150 | 0.958 | 367.01 | 0.385 | 0.879 | 1.096 | 0.397 | 1.562 | 0.254 | 0.665 |
| 4FNY | 1.092 | 195 | 1.161 | 426.349 | 0.556 | 0.724 | 0.932 | 1.470 | 0.654 | 2.249 | 1.858 |

Table 3: Properties of docking sites of receptors:

The docking site score of 2AZ1 (1.121) receptor/protein is higher while that of 2BOU (0.464) is lowest is indicates that the 2AZ1 protein PDB is more favorable for docking than the others. The size (223) and volume (760.774) available for docking is higher in 4BBG and 3FDN PDBs respectively but exposure to the ligand as compared to 2BOU is lower. The exposure to the ligand is maximum in 2BOU and minimum in 2AZ1 while reverse is the case for the enclosure area, it is higher in 2AZ1 and minimum in 2BOU. The overall contact area to the ligand is higher in 1RJB (1.124). The hydrophobic nature or character and balance between hydrophobic and hydrophilic nature of the active site is higher in 2AZ1 and lower in 1TE6. The hydrophilic nature or character of the active site is higher in 2AZ1 and lower in 4FNY. The ligands having more hydrophilic nature are more tightly binds with 1TE6 and weakly binded to 4FNY (according to the hydrophobic to hydrophilic ratio i.e. balance is higher in 4FNY than lower in 1TE6).

The order protein in the decreasing order of hydrophilic character and increasing order of hydrophobic character is -1TE6 > 2BOU > 2AZ1 > 3F8S > 1BAG > 1KDR > 1P62 > 3V3M > 1Z92 > 1UFQ > 1RJB > 3FDN > 3MK2 > 4BBG > 1VOM > 3LAU > 1YCR > 2b4J > 4FNY. This indicates that the ligands having more hydrophobic nature are binds easily 4FNY. The hydrogen bond donor/acceptor character ratio is higher in 1YCR (2.006) while lower in 1BAG (0.478) therefore the ligand contains more hydrogen bond acceptor atoms/groups are more tightly binds to 1YCR while those containing hydrogen bond donor to H-bond acceptor ratio is <math>-1YCR > 4FNY > 2b4J > 2BOU > 1Z92 > 1UFQ > 3FDN > 3F8S > 3LAU > 4BBG > 1VOM > 1RJB > 2AZ1 > 1KDR > 3MK2 > 1TE6 > 1P62 > 3V3M > 1BAG.

4.2. Molecular docking:

The estimation of binding affinity of the ligand-receptor/protein complex is still a challenging task. Scoring functions (docking score) in docking programs take the ligand-receptor/protein poses as input and provides ranking or estimation of the binding affinity of the pose. These scoring functions require the availability of receptor/protein-ligand complexes with known binding affinity and use the sum of several energy terms such as *van der Waals* potential, electrostatic potential, hydrophobicity and hydrogen bonds in binding energy estimation. The second class consists of *force field-based scoring functions*, which use atomic force fields used to calculate free energies of binding of ligand-receptor/protein complex.


| Description | Protein | | | | | | | | | |
|---------------|---------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| | 1BAG | 1YCR | 1Z92 | 2b4J | 3F8S | 1TE6 | 1YOM | 2BOU | 3MK2 | 1KDR |
| Potential | 77.188 | 77.188 | 77.188 | 77.188 | 77.188 | 77.188 | 77.188 | 77.188 | 77.188 | 77.188 |
| Energy | | | | | | | | | | |
| OPLS 2005 | | | | | | | | | | |
| RMS | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| Derivative | | | | | | | | | | |
| OPLS 2005 | | | | | | | | | | |
| Glide lignum | 13 | 13 | 13 | 3 | 3 | 11 | 11 | 11 | 11 | 11 |
| Docking | -5.315 | -4.914 | -5.242 | -4.098 | -4.61 | | | | | -4.205 |
| Score | | | | | | -3.525 | -6.97 | -4.30 | -5.453 | |
| Glide Ligand | -0.253 | -0.234 | -0.250 | -0.195 | -0.220 | | | | | -0.20 |
| efficiency | | | | | | -0.168 | -0.332 | -0.205 | -0.26 | |
| Glide Ligand | -0.698 | -0.646 | -0.689 | -0.538 | -0.606 | -0.463 | | | | -0.552 |
| efficiency sa | | | | | | | -0.916 | -0.565 | -0.716 | |
| Glide Ligand | -1.314 | -1.215 | -1.296 | -1.013 | -1.140 | -0.872 | | | | |
| efficiency In | | | | | | | -1.723 | -1.063 | -1.348 | -1.04 |
| Glide gscore | -5.315 | -4.914 | -5.242 | -4.098 | -4.61 | -3.525 | -6.97 | -4.30 | -5.453 | -4.205 |
| glide lipo | -1.439 | -2.155 | -1.649 | -0.671 | -1.222 | -0.448 | -3.120 | -1.27 | -1.995 | -0.761 |
| glide hbond | -0.160 | 0 | -0.055 | 0 | -0.060 | -0.079 | -0.320 | -0.227 | -0.369 | -0.336 |
| glide metal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| glide rewards | -1.828 | -1.526 | -1.688 | -1.708 | -1.484 | -1.484 | -1.654 | -1.487 | -1.628 | -1.484 |
| Glide evdw | - | - | - | - | - | - | - | - | - | - |
| | 29.249 | 26.565 | 29.280 | 26.962 | 27.370 | 24.728 | 33.446 | 23.618 | 29.017 | 30.618 |
| Glide ecoul | -3.893 | -0.874 | -4.086 | -3.982 | -4.251 | -3.197 | -3.203 | -2.309 | -1.583 | -2.077 |
| glide erotb | 0.227 | 0.227 | 0.227 | 0.227 | 0.227 | 0.227 | 0.227 | 0.227 | 0.227 | 0.227 |
| glide esite | -0.068 | 0 | 0 | 0 | -0.064 | -0.026 | 0 | 0 | 0 | -0.008 |
| Glide emodel | - | - | - | - | - | - | - | - | - | - |
| | 44.766 | 33.887 | 43.066 | 37.685 | 41.015 | 35.207 | 49.033 | 32.658 | 40.870 | 41.602 |
| Glide energy | - | - | - | - | - | - | - | - | - | - |
| | 33.142 | 27.439 | 33.366 | 30.945 | 31.622 | 27.926 | 35.650 | 26.294 | 30.599 | 32.694 |
| Glide | 0.407 | 5.154 | 2.144 | 1.468 | 0.786 | | | | 0.084 | 0.44 |
| einternal | | | | | | 0.810 | 3.969 | 0.835 | | |
| glide | 1 | | | | | 1 | | | | |
| confnum | | 2 | 1 | 1 | 2 | | 2 | 1 | 2 | 1 |
| Glide | 374 | 395 | 33 | 364 | 361 | 174 | | | | 139 |
| posenum | | | | | | | 304 | 06 | 39 | |
| XP GScore | -5.315 | -4.914 | -5.242 | -4.098 | -4.61 | -3.525 | -6.97 | -4.30 | -5.453 | -4.205 |
| H-Bonds | 01 | 00 | 01 | 00 | 01 | 01 | 01 | 00 | 01 | 01 |
| pi-pi/pi- | 00 | 00 | 01 | 01 | 01 | 00 | 02 | 00 | 03 | 04 |
| cation | | | | | | | | | | |
| interactions | | | | | | | | | | |


| Table 4A: Docking properties of | 7-methoxy-2-(3-methoxyphenyl)-1-benzofuran-5-carbaldehyde with |
|-------------------------------------|--|
| different receptor or protein PDBs. | |


| Description | Protein | | | | | | | | |
|-----------------------------------|---------|---------|--------|--------|--------|--------|--------|--------|--------|
| | 1P62 | 1UFQ | 2AZ1 | 4FNY | 1RJB | 3FDN | 3LAU | 3V3M | 4BBG |
| Potential Energy OPLS 2005 | 77.188 | 77.188 | 77.188 | 77.188 | 77.188 | 77.188 | 77.188 | 77.188 | 77.188 |
| RMS Derivative OPLS 2005 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| Glide lignum | 11 | 11 | 11 | 11 | 9 | 9 | 6 | 9 | 10 |
| Docking Score | -4.547 | -4.843 | -4.094 | -7.159 | -5.789 | -5.897 | -6.659 | -3.373 | -6.494 |
| Glide Ligand efficiency | -0.217 | -0.231 | -0.195 | -0.341 | -0.276 | -0.281 | -0.317 | -0.161 | -0.309 |
| Glide Ligand | -0.597 | -0.636 | -0.538 | -0.941 | -0.761 | -0.775 | | | |
| efficiency sa | | | | | | | -0.875 | -0.443 | -0.853 |
| Glide Ligand efficiency In | -1.124 | -1.197 | -1.012 | -1.77 | -1.431 | -1.458 | -1.646 | -0.834 | -1.606 |
| Glide gscore | -4.547 | -4.843 | -4.094 | -7.159 | -5.789 | -5.897 | -6.659 | -3.373 | -6.494 |
| glide lipo | -0.813 | -1.211 | -0.794 | -4.022 | -1.643 | -1.648 | -3.084 | -2.121 | -1.398 |
| glide hbond | 0.18 | -0.32 | -0.153 | 0 | -0.398 | -0.349 | -0.049 | -0.421 | -0.039 |
| glide metal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| glide rewards | -1.484 | -1.484 | -1.484 | -1.699 | -1.638 | -1.636 | -1.818 | -1.486 | -1.482 |
| Glide evdw | - | -29.388 | - | - | - | - | - | - | - |
| | 30.505 | | 31.514 | 33.746 | 34.704 | 34.061 | 32.022 | 28.634 | 34.234 |
| Glide ecoul | -4.625 | -3.771 | -1.704 | -0.151 | -4.01 | -4.366 | -1.949 | -3.76 | -1.306 |
| glide erotb | 0.227 | 0.227 | 0.227 | 0.227 | 0.227 | 0.227 | 0.227 | 0.227 | 0.227 |
| glide esite | -0.077 | -0.019 | -0.059 | 0 | 0 | 0 | -0.042 | -0.024 | 0 |
| Glide emodel | - | -41.967 | - | - | - | - | - | - | - |
| | 45.275 | | 41.559 | 47.445 | 48.297 | 47.132 | 47.922 | 36.166 | 38.437 |
| Glide energy | - | -33.159 | - | - | - | - | - | - | - |
| | 35.130 | | 33.215 | 33.594 | 38.714 | 38.427 | 33.970 | 32.394 | 35.359 |
| Glide einternal | 1.645 | 3.851 | 2.717 | 1.057 | 7.672 | 6.049 | 0.268 | 6.208 | 7.426 |
| glide confnum | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 |
| Glide posenum | 246 | 289 | 367 | 248 | 337 | 7 | 246 | 4 | 3 |
| XP GScore | -4.547 | -4.843 | -4.094 | -7.159 | -5.789 | -5.897 | -6.659 | -3.373 | -6.494 |
| H-Bonds | 01 | 02 | 01 | 00 | 01 | 2 | 01 | 01 | 00 |
| 00pi-pi/pi-cation interactions | 04 | 00 | 00 | 00 | 01 | 00 | 00 | 00 | 00 |


 Table 4B: Docking properties of 7-methoxy-2-(3-methoxyphenyl)-1-benzofuran-5-carbaldehyde with different receptor or protein PDBs.


Fig 4: 2D docking image of 7-methoxy-2-(3-methoxyphenyl)-1-benzofuran-5-carbaldehyde with different proteins:














3F8S




2b4J




1YCR






4FNY GLY 1269 ASP 1270 PHE 1271 VAL 1180 II96 VAL 1130 LEU 1256 148 1122 1197 1197 GLY 1202 LEU 1198 ASP 1203 Ì ALA 1200 GUU




1UFQ







al



2AZ1


1KDR





3MK2

1TE6







Fig 5: 3D docking image of 7-methoxy-2-(3-methoxyphenyl)-1-benzofuran-5-carbaldehyde with different proteins:

1RJB


ALAU

3FDN

4BBG




3V3M





1YCR






2b4J







5. Cytotoxic study:

41Y 192

Lung cancer cell line (A459) and Breast cancer cell lines (MCF-07) was selected as a test system because it is a commonly available cancer cell lines. It has been historically shown to be a suitable cell line module for cytotoxicity studies. The study was conducted in based on

the in house standardized method and available literature to determine the cytotoxicity of test compound. The cancerous cell line viz. Breast (MCF - 07) and Lung (A - 549) were procured from National Center of Cell Science, Pune. The cells were allowed to acclimatize to the experimental laboratory conditions for a period of five days by regular pass aging of cells. Cell pass aging was done in the cell culture experimental room. Before the start of experiment the room was sterilized by keeping UV on for 20 minutes. The culture flasks were kept in 5% CO₂ incubator at 37^{0} C. The experimental room was cleaned and mopped daily with Liquid disinfectant. Each column was dedicated for specific test compound while two columns were used as cell control and two as positive control. Cells were exposed to the test compound for the period of around 18-24 hours.

Samples were freshly prepared in DMEM without phenol Red and then appropriate dilutions were prepared just prior to start of study. Cell viability assay was performed as per the standard procedure. The obtained data was subjected to statistical evaluation. CC50 values were calculated as the concentrations that show 50% inhibition of proliferation on the cell line.

| Conc. mg/ml | MTT assay | | MB assay | | | |
|-------------|---------------|----------------|---------------|----------------|--|--|
| _ | A – 459 cells | MCF - 07 cells | A – 459 cells | MCF - 07 cells | | |
| 10 | 86.10 | 95.97 | 90.97 | 90.67 | | |
| 7.5 | 66.16 | 91.26 | 72.48 | 69.07 | | |
| 5.0 | 51.34 | 81.85 | 49.03 | 50.43 | | |
| 2.5 | 35.68 | 74.79 | 40.19 | 34.10 | | |
| 1.0 | 24.85 | 59.26 | 34.97 | 23.02 | | |
| 0.50 | 18.02 | 29.15 | 26.39 | 15.60 | | |
| 0.25 | 10.33 | 14.09 | 19.56 | 0.74 | | |
| 0.10 | 5.20 | 1.85 | 7.10 | 3.44 | | |

 Table 5: Percent cytotoxicity

6. Result and discussion:

The PBD 1YCR has more hydrogen bond donor character while the PDB 1BAG has more hydrogen bond accepting character at the docking site. The docking score table indicate that 7-methoxy-2-(3-methoxyphenyl)-1-benzofuran-5-carbaldehyde is more active against 4FNY (docking score -7.159) and 1VOM (docking score -6.970) while is less active against 3V3M (docking score -3.373) and 1YE6 (docking score -3.525). There are number of types of interactions observed between ligand and receptor such as hydrogen bonding, pi-pi interactions, ion-pi interactions, hydrophobic and hydrophilic interactions, ionic interactions, van der Waal interactions, etc along with steric interactions determine the docking score.

 Table 6: Table of don/acc ratio, docking score, glide esite and polar interactions of 7-methoxy-2-(3-methoxyphenyl)-1-benzofuran-5-carbaldehyde with different receptor or protein PDBs.

| Proteins | Description of property and amino acid information | | | | | | | | |
|----------|--|------------------|----------------|---|---|--|--|--|--|
| | don/acc at the docking site | Docking score | Glide esite | No. of hydrogen bonds (amino acid residues) | Polar interactions (amino acid residues) (J-J, J- cation) | | | | |
| 1RJB | 0.706 | -5.789 | 0 | 01 (ARG595) (with side chain) | ARG595 | | | | |
| 3FDN | 0.880 | -5.897 | 0 | 02 (ARG137) (with side chain), (ALA213) (with backbone) | | | | | |
| 3LAU | 0.749 | -6.659 | -0.042 | 01 (ARG220) (with side chain) | | | | | |
| 4BBG | 0.725 | -6.494 | 0 | | | | | | |

| 3V3M | 0.510 | -3.373 | -0.024 | 01 (GLN110) (with side | |
|------|-------|--------|--------|--|-------------------------------------|
| | | | | chain) | |
| 1BAG | 0.478 | -5.315 | -0.068 | 01 (ARG174) (with side chain) | |
| 3F8S | 0.762 | -4.61 | 0 | 01 (TYR547) (with side chain) | PHE357 |
| 2b4J | 1.456 | -4.098 | 0 | | C-LYS360 |
| 1Z92 | 1.427 | -5.242 | 0 | 01 (A-LYS76) (with side chain) | A-LYS535 |
| 1YCR | 2.006 | -4.914 | 0 | | |
| 4FNY | 1.858 | -7.159 | 0 | | |
| 2BOU | 1.433 | -4.300 | 0 | | |
| 1UFQ | 0.931 | -4.843 | -0.019 | 02 (C-LYS202, D-LYS202) (with side chain) | |
| 1VOM | 0.708 | -6.970 | 0 | 01 (TYR135) (with side chain) | PHE129, PHE129 |
| 2AZ1 | 0.665 | -4.094 | -0.059 | 01 (A-ARG19) (with side chain) | |
| 1KDR | 0.661 | -4.205 | -0.008 | 01 (GLY19) (with backbone) | ARG41, ARG131, ARG41, ARG131 |
| 1P62 | 0.520 | -4.547 | -0.027 | 01 (ARG128) (with side chain) | ARG194 (with three rings), LYS34 |
| 3MK2 | 0.623 | -5.453 | 0 | 01 (ASN134) (with side chain) | ARG125, HID162, HID162 |
| 1TE6 | 0.595 | -3.525 | -0.026 | 01 (B-ARG14) (with side chain) | |

Glide esite explains the polar interaction in the active site between ligand and amino acid residue at the docking site after recombination. The polar interactions between the aldehyde and amino acid residues of the protein are only observed in 1BAG (-0.068), 2AZ1 (-0.059), 3LAU (-0.042), 1P62 (-0.027), 1TE6 (-0.026), 3V3M (-0.024), 1UFQ (-0.019) and 1KDR (-0.008) while these are totally absent with remaining PDBs. The aldehyde shows higher polar interaction 3MK2, 1VOM, 1BAG, 1TE6, 3V3M, and 2b4J proteins PDBs. This is one of the reason for the higher docking score of aldehyde in 1VOM. Also the molecule containing three hydrogen atom acceptors and hydrogen atom donor character of 4FNY at docking site is higher. The docking score of aldehyde during docking with 4FNY is higher (even though there is absence of hydrogen bonding and stronger pi-cation/anion interactions and polar interactions) because the molecule is completely fit into docking site with minimum internal strain and deformation of the geometry.

The aldehyde does not have any hydrogen atom which is capable of forming L (ligand) \rightarrow P (protein) hydrogen bonding. It contains sp² and sp³ hybridized oxygen atoms (carbonyl, ether and aromatic) capable of forming P \rightarrow L type of hydrogen bonding during interaction. The backbone of ALA and GLY amino acids and side chain of ARG, GLN, TYR, ASN and LYS forming hydrogen bonding with ligand.

| Proteins | Proteins Description of property and amino acid information | | | | | | | | | |
|----------|---|---------|---------------------|---------|--------------|----------|------------|--------------|--|--|
| | Glide | Glide | Electrostati | c | Electrostati | c | Polar | interactions | | |
| | evdw | energy | interactions (blue) | | interactions | s (pink) | (amino aci | d residues) | | |
| 1RJB | -34.704 | -38.714 | ARG595 | | GLU573, | ASP593, | SER574, | GLN577, | | |
| | | | | | GLU656, G | LU661 | SER660 | | | |
| 3FDN | -34.061 | -38.427 | ARG137, | LYS141, | GLU211, G | LU260 | THR217, A | ASN261 | | |
| | | | LYS162 | | | | | | | |
| 3LAU | -32.022 | -33.970 | ARG137, | LYS162, | GLU211 | | | | | |

 Table 7: Table of glide evdw, glide energy, electrostatic and polar interactions 7-methoxy-2-(3-methoxyphenyl)-1-benzofuran-5-carbaldehyde with different receptor or protein PDBs.

 Determine the second se

| | | | ARG220 | | |
|------|---------|---------|--|---|--|
| 4BBG | -34.234 | -35.539 | ARG119, ARG221 | GLU116, GLU118, ASP130, GLU215 | |
| 3V3M | -28.634 | -32.394 | | GLU240 | GLN107, GLN110, ASN203, HIE246, THR292 |
| 1BAG | -29.249 | -33.142 | ARG174 | ASP176, ASP269 | GLN63, ASN101, HID102, GLN208, HID268, ASN273 |
| 3F8S | -27.370 | -31.622 | ARG429, LYS554, ARG669 | GLU205, GLU206 | SER209, SER552, GLN553 |
| 2b4J | -26.962 | -30.945 | C-LYS360, C- LYS364, C-LYS402 | C-GLU395 | A-GLN164, A-GLN168, C-THR398, C-THR399 |
| 1Z92 | -29.280 | -33.366 | A-LYS32, A-LYS35, A-LYS76 | B-ASP-1, B-GLU1 | A-ASN33, A-ASN71, A- GLN74 |
| 1YCR | -26.565 | -27.439 | A-LYS51, B-LYS24 | A-GLU52, B-GLU28 | |
| 4FNY | -33.746 | -33.594 | | GLU1132, GLU1197, ASP1203, ASP1270 | |
| 2BOU | -23.618 | -26.294 | ARG22 | GLU32 | SER28, SER29, SER31 |
| 1UFQ | -29.388 | -33.159 | C-LYS202, D- LYS201, D-LYS202 | C-GLU194, C- GLU195, D-GLU194, D-GLU195 | |
| 1VOM | -33.446 | -35.650 | LYS130, ARG131 | GLU187 | ASN127, ASN188, ASN233, ASN234, ASN235, GLN665 |
| 2AZ1 | -31.514 | -33.215 | A-ARG19, B- ARG147, E-ARG19 | A-GLU30, E-ASP24 | B-THR27, B-THR31, D- THR31 |
| 1KDR | -30.618 | -32.694 | LYS18, ARG41, ARG131, ARG158, ARG181 | | SER14, SER101, GLN161 |
| 3MK2 | -29.017 | -30.599 | ARG125 | GLU128, GLU181 | THR124, ASN134, HID162, GLN184, GLN189, ASN193 |
| 1TE6 | -24.728 | -27.926 | A-LYS192, A- LYS196, A-LYS201, B-ARG14 | B-ASP208 | A-HID189, A-THR190, A-THR204, B-SER156, B-HID157 |
| 1P62 | -30.505 | -35.130 | LYS34, ARG128, ARG188, ARG192, ARG194 | GLU53, GLU127, GLU197 | SER35, THR37 |

Glide evdw explains the van der Waal energy of the complex of ligand and amino acid residue at the docking site after recombination. The comparison between glide evdw and glide energy shows that van der Waal energy shows major contribution than coulombic energy for the stabilization of complex. The van der Waal interaction is depends on surface area (polar and non-polar) of the ligand, as surface area increases, van der Waal energy increases and vice versa. The contribution of glide evdw into the docking score is considerable. The Glide evdw of the interaction in decreasing order is as 1RJB > 4BBG > 3FDN > 4FNY > 1VOM > 3LAU > 2AZ1 > > 2BOU.

Glide energy is summation of coulomb and van der Waal energy of interaction. The glide energy table indicates that, the comparatively coulombic force and van der Waal interactions (energies) are higher for the aldehyde-1RJB complex. This is due to higher surface area (both polar and non-polar) of 1RJB available for interaction with aldehyde. The aldehyde has higher glide energy during the interaction with PBDs in the decreasing order as 1RJB > 3FDN > 1VOM > 4BBG > 1P62 > 3LAU > 4FNY > > 2BOU.

Along with major interactions, there are some other interactions such polar interactions (faint blue colour), hydration sites (orange, interaction with water), electrostatic interactions (blue

and pink) and hydrophobic interaction (major weak interaction with maximum number of amino acids) present between the ligand-protein complex.

The table 7 [Electrostatic interactions (blue)] shows that, two amino acids in all proteins as ARG and LYS shows positive interactions (hydrogen bonding between proton of protein and O/N of ligand or electrostatic interaction between positive centre of protein and negative / electron density of ligand). Both the amino acids containing amino group in their side chain which is capable of forming such type of interactions in neutral or protonated forms. Benzofuran aldehyde shows stronger such type of interaction with same amino acids of 1P62, 1KDR, 1TE6, 2AZ1, 1Z92, 1UFQ, 2b4J, 3F8S, 3LAU and 3FDN indicates that orientation of the molecule does not change during docking in major extend by the changing of skeleton or functional group. But such type of interaction is weaker in 1RJB, 1BAG, 2BOU and 3MK2 whereas is absent with 3V3M and 4FNY.

The table 7 [Electrostatic interactions (pink)] shows that, two amino acids in all proteins as ASP and GLU shows negative interactions (hydrogen bonding between proton of ligand and oxygen of protein or electrostatic interaction between positive centre of ligand and negative / electron density of protein). Both the amino acids containing carboxylic acid group in their side chain which is capable of forming such type of interactions in neutral or deprotonated form. This type interaction depends on the number of positive charge centre present in the ligand molecules and number of donor amino acids present in the docking site. 1RJB, 4BBG, 4FNY, 1UFQ and 1P62 PDBs shows maximum number of such type of interactions with aldehyde while 3LAU, 3V3M, 2BOU, 2b4J, 1VOM and 1TE6 shows minimum number of such interactions and are absent in 1KDR.

Benzofuran aldehyde molecule is hydrophobic in nature, even though it has strong region for hydrogen bonding, pi-pi interactions and hydrophobic interactions. This interaction would trigger the change in orientation of structure and their groups during binding. The group of aldehyde such as C=O, -O-, aromatic -O- groups/atoms are capable for the formation of hydrogen bonding. The aromatic ring and $-CH_3$ group put some limitations in the packing of micellar rearrangement as well as reducing the chance of forming hydrogen bonding with amino acids residue of protein.

| Proteins | Description of property and amino acid information | | | | | | | |
|----------|--|--------|------------------------|------------------------|----------|--|--|--|
| | Glide Pi-pi interactions (green) | | Pi-cation interactions | | | | | |
| | phobic | philic | lipo | | (pink) | | | |
| 1RJB | 0.668 | 1.186 | -1.643 | ARG595 | | | | |
| 3FDN | 0.758 | 1.170 | -1.648 | | | | | |
| 3LAU | 1.245 | 0.819 | -3.084 | | | | | |
| 4BBG | 1.274 | 1.108 | -1.398 | | | | | |
| 3V3M | 0.473 | 1.200 | -2.121 | | | | | |
| 1BAG | 0.343 | 1.103 | -1.439 | | | | | |
| 3F8S | 0.298 | 1.089 | -1.222 | PHE357 | | | | |
| 2b4J | 1.321 | 0.765 | -0.671 | | C-LYS402 | | | |
| 1Z92 | 0.396 | 0.805 | -1.649 | | A-LYS35 | | | |
| 1YCR | 1.171 | 0.675 | -2.155 | | | | | |
| 4FNY | 1.470 | 0.654 | -4.022 | | | | | |
| 2BOU | 0.134 | 1.000 | -1.270 | | | | | |
| 1UFQ | 0.510 | 0.947 | -1.211 | | | | | |
| 1VOM | 1.022 | 0.853 | -3.120 | PHE129, PHE129 | | | | |
| 2AZ1 | 0.397 | 1.562 | -0.794 | | | | | |
| 1KDR | | | | ARG41, ARG41, ARG131, | | | | |
| | 0.463 | 1.343 | -0.761 | ARG131 | | | | |
| 3MK2 | 0.632 | 0.717 | -1.995 | ARG125, HID162, HID162 | | | | |

Table 8: Table of glide lipo and polar interactions of 7-methoxy-2-(3-methoxyphenyl)-1-benzofuran-5carbaldehyde with different receptor or protein PDBs, hydrophobic and hydrophilic character of PDBs.

| 1TE6 | 0.008 | 1.703 | -0.448 | | |
|------|-------|-------|--------|----------------|---------------|
| 1P62 | 0.49 | 1.393 | -0.813 | ARG194, ARG194 | ARG194, LYS34 |

Glide lipo explains the lipophilic and lipophobic attraction between ligand and amino acid residue at the docking site after recombination. The molecule is undissociated and thus available for penetration through various lipid barriers. The rate of penetration is strongly depends on the lipophilicity of the drug molecule in its unionised form. The lipophilic-hydrophilic balance plays very important role in passive transport and active transport along with drug metabolism. As length of hydrophobic chain increases, both partion coefficient and anaesthetic potency increases. Lipophilic and phobic attraction between aldehyde and amino acid residue at the docking site is stronger with 4FNY, 3LAU, 1P62, 1BAG, 1YCR, 1RJB PDBs at the neutral pH = 7. At lower pH, amine get protonated and its lipophilicity character goes on decreasing. The aldehyde shows weaker lipophilic and hydrophobic attraction with 1TE6, 1P62, 2AZ1, 1KDR, 2BOU and 1BAG.

The electron rich pi-system (containing electron donating group) are generally interact with other electron deficient pi-system having electron withdrawing group. These are denoted by green colour and are called as hydrophobic interactions. Also, electron rich pi-centre interacts with cation (denoted by dark blue colour) and electron deficient centre interact with anion (denoted by pink colour). The benzofuran aldehyde shows the pi-pi interactions with the amino acid residue containing aromatic ring or pi electrons, the amino acids such as ARG (C=N bond) and PHE & HID (aromatic ring) shows such interactions with aldehyde. The pication interaction are shown by those amino acid residue containing free cation or partial positive charge centre in their side chain such as LYS and ARG, both containing amino groups which get protonated and forming quaternary ammonium cation which get interact with airomatic ring. These type of interactions are depends on the orientation of the molecule in the docking site and amino acid arrangement in the same.

Based on the results of MTT and MB assay, it is concluded that 7-methoxy-2-(3-methoxyphenyl)-1-benzofuran-5-carbaldehyde more toxic against breast cancer cell line and cancerous lung cell line.

7. Acknowledgement:

The authors are grateful to the Principal and Head, Government of Maharashtra, Ismail Yusuf Arts, Science and Commerce College, Mumbai 60, India, and Principal and Head, Department of Chemistry, Patkar Varde College, Goregaon (W), Mumbai, India for his constant encouragement. For the spectral analyses and characterization, basic facilities and helpful discussions during the synthesis the authors are thankful to Ram Jadhav, Dr. Dileep Khandekar, Dr. D D Patil.

The authors are specially thankful to Schrodinger software company group for their help and support.

8. References:

- 1. Leach, A. R. Molecular Modelling: Principles and Applications, Second Edition, Published by Pearson Education EMA, January 2001.
- 2. Ooms, F., Molecular modelling and computer aided drug design. Examples of their applications in medicinal chemistry. Curr. Med. Chem. **2000**, *7* (2), 141-158.
- 3. Halperin I, Ma B, Wolfson H, and Nussinov R. Principles of docking: An overview of search algorithms and a guide to scoring functions. PROTEINS: Structure, Function, and Genetics, 2002, 47:409-443.

- 4. Acc Chem Res 1996;29: Several articles in issue 3.
- 5. Fernandes P. B. Technological advances in high-throughput screening. Curr Opin Chem Biol, 1998;2:597-603.
- 6. Hertzberg RP, Pope AJ. High-throughput screening: Newtechnology for the 21st century. Curr Opin Chem Biol 2000;4:445-451.
- Clark DE. Computational prediction of ADMET properties: Recent developments and 7. future challenges. Annu Rep Comput Chem 2005;1:133–151.
- 8. Bapu R Thorat; Dyneshwar Shelke; Ramdas Atram and Ramesh Yamgar, wittig reaction approach for the synthesis of 7-methoxy-2-[4-alkyl/aryl]-l-benzofuran-5carboxaldehyde, hl, vol. 3: (3), 2013, 385-396.

| Table: Molecular properties of 7-methoxy-2-(3-methoxylphenyl)-1-benzofuran-5-carbaldehyde | | | | | | | | |
|---|-----------------|-----------|------------|--------------------|--|--|--|--|
| mol MW | dipole | SASA | Donor HB | Accpt HB | | | | |
| 282.295 | 4.278 | 546.524 | 0 | 4 | | | | |
| Potential Energy- | RMS Derivative- | | | | | | | |
| OPLS-2005 | OPLS-2005 | volume | dip^2/V | Glob | | | | |
| 77.188 | 0.004 | 918.257 | 0.01993 | 0.835985 | | | | |
| FOSA | FISA | PISA | WPSA | ACxDN^.5/SA | | | | |
| 202.644 | 77.289 | 266.592 | 0 | 0 | | | | |
| QPpolrz | QPlogPC16 | QPlogPoct | QPlogPw | QPlogPo/w | | | | |
| 31.214 | 9.078 | 12.333 | 6.652 | 3.115 | | | | |
| QPlogS | CIQPlogS | QPlogHERG | QPPCaco | QPlogBB | | | | |
| -3.991 | -4.112 | -5.457 | 1832.185 | -0.355 | | | | |
| | | | Human Oral | Percent Human Oral | | | | |
| QPPMDCK | QPlogKp | IP(eV) | Absorption | Absorption | | | | |
| 951.894 | -1.717 | 8.69 | 3 | 100 | | | | |
| SAfluorine | SAamideO | PSA | #NandO | Rule Of Five | | | | |
| 0 | 0 | 61.719 | 4 | 0 | | | | |
| Rule Of Three | EA(eV) | #metab | QPlogKhsa | #ringatoms | | | | |
| 0 | 0.812 | 3 | 0.086 | 15 | | | | |
| #in34 | #in56 | #noncon | #nonHatm | Jm | | | | |
| 0 | 15 | 0 | 21 | 0.553 | | | | |

SUPPORTING DATA

Received on December 25, 2014,